Chronic Hepatitis B Diagnosis and Management

Core Serologic Markers

The American Association for the Study of Liver Diseases recommends that HBsAg positivity for >6 months, along with positive markers including anti-HBc (IgG) and detectable HBV DNA, is definitive for chronic hepatitis B diagnosis 1, 2
HBsAg is the hallmark marker that must be positive for >6 months to establish chronic infection, as stated by the American Association for the Study of Liver Diseases 3, 1, 4, 5
Anti-HBc total (IgG) confirms chronic rather than acute infection and is universally positive in chronic hepatitis B, according to the American Association for the Study of Liver Diseases 6, 7

In HBeAg-positive chronic hepatitis B, the American Association for the Study of Liver Diseases indicates that HBeAg positive indicates active viral replication and high infectivity 3, 1, 6
The American Association for the Study of Liver Diseases states that HBV DNA >20,000 IU/mL is typically seen in HBeAg-positive disease, often 200,000-2 billion IU/mL 1, 2
In HBeAg-negative chronic hepatitis B, the American Association for the Study of Liver Diseases recommends that HBeAg negative and anti-HBe positive indicate lower replication states 1, 2, 7
The American Association for the Study of Liver Diseases indicates that HBV DNA >2,000 IU/mL is seen in HBeAg-negative disease, typically 2,000-20 million IU/mL 1, 2

The Centers for Disease Control and Prevention recommends that liver function tests, including albumin and prothrombin time/INR, reflect synthetic function and may be normal in early disease or abnormal in advanced disease 9, 8
The American Association for the Study of Liver Diseases states that AFP (alpha-fetoprotein) is used for HCC surveillance, not diagnostic of chronic hepatitis B itself 9

The American Association for the Study of Liver Diseases recommends that serial testing is mandatory because chronic hepatitis B is a dynamic disease with fluctuating markers 1, 2, 7
The American Association for the Study of Liver Diseases states that normal ALT does not exclude significant disease, as patients in the immune tolerant phase may have high HBV DNA (>20,000 IU/mL) with normal transaminases but still progress to cirrhosis and HCC 3, 6, 8
The American Association for the Study of Liver Diseases indicates that 10-30% of inactive carriers reactivate with elevated ALT and high HBV DNA after years of quiescence, requiring lifelong monitoring every 6-12 months 2, 7
The American Association for the Study of Liver Diseases recommends that HBV DNA quantification is essential for proper classification and cannot be omitted 1, 7
The Centers for Disease Control and Prevention states that coinfection testing is critical, and all patients should be tested for anti-HCV, anti-HDV, and anti-HIV in at-risk populations 10, 9